Meeting
2014 ASCO Annual Meeting
Phase II trial of oxaliplatin and 5-FU in patients (pts) with platinum-resistant recurrent (PRR) ovarian carcinoma (OVCA).
Authors
Joseph N. Kerger
Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Joseph N. Kerger , Fabienne Lebrun , Thierry Gil , Andrea Gombos , Amina Ridoine , Fanny Bustin , Veronique D'hondt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01481701
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 5580)
DOI
10.1200/jco.2014.32.15_suppl.5580
Abstract #
5580
Poster Bd #
362
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.
First Author: Jean-Louis Legoux
Poster
2022 ASCO Annual Meeting
PERCEPTION: Phase II investigational study of pembrolizumab combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer— A NOGGO trial.
First Author: Jacek P. Grabowski
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore
Poster
2018 ASCO Annual Meeting
A phase II trial of bevacizumab-GemAOD regimen for newly diagnosed extranodal NK/T cell lymphoma.
First Author: Zhiming Li